Literature DB >> 28939672

CHA2DS2-VASc Score for Identifying Truly Low-Risk Atrial Fibrillation for Stroke: A Korean Nationwide Cohort Study.

Tae-Hoon Kim1, Pil-Sung Yang1, Daehoon Kim1, Hee Tae Yu1, Jae-Sun Uhm1, Jong-Youn Kim1, Hui-Nam Pak1, Moon-Hyoung Lee1, Boyoung Joung2, Gregory Y H Lip1.   

Abstract

BACKGROUND AND
PURPOSE: As the threshold of stroke risk for initiating oral anticoagulants is lowered after the introduction of the nonvitamin K antagonist oral anticoagulants, the focus of stroke prevention in patients with nonvalvular atrial fibrillation has shifted away from predicting high-risk patients toward initially identifying patients with a truly low risk of ischemic stroke, who do not need antithrombotic therapy. We tested the predictive ability of the congestive heart failure, hypertension, age ≥75, diabetes mellitus, prior stroke or transient ischemic attack (doubled; CHADS2), congestive heart failure, hypertension, age ≥75 (doubled), diabetes mellitus, prior stroke or transient ischemic attack (doubled), vascular disease, age 65 to 74, female (CHA2DS2-VASc), and Anticoagulation and Risk Factors in Atrial Fibrillation (ATRIA) risk stratification schemes in oral anticoagulants naive patients with atrial fibrillation in a Korean nationwide sample cohort.
METHODS: From January 2002 to December 2008, a total of 5855 oral anticoagulant naive patients with nonvalvular atrial fibrillation aged ≥20 years were enrolled from Korea National Health Insurance Service-Sample Cohort database and were followed-up until December 2013.
RESULTS: At baseline, the proportions categorized as low risk using CHADS2, CHA2DS2-VASc, and ATRIA risk stratification schemes were 1049 (17.9%), 860 (14.7%), and 3280 (56.0%), respectively. During follow-up, the low-risk category using CHADS2, CHA2DS2-VASc, and ATRIA scores was retained in 811 (13.9%), 667 (11.4%), and 2729 (46.6%) patients, respectively. Rates of ischemic stroke (100 person-years) in the low risk categories of CHADS2, CHA2DS2-VASc, and ATRIA scores were 0.42, 0.26, and 1.43, respectively. CHA2DS2-VASc had the best sensitivity (98.8% versus 85.7% in CHADS2 and 74.8% in ATRIA) and negative predictive value (98.8% versus 95.3% for CHADS2 and 93.7% for ATRIA) for the prediction of stroke incidence and was best for the prediction of the absence of ischemic stroke during 5 years of follow-up (odds ratio, 16.4 [95% confidence interval, 8.8-30.8]).
CONCLUSIONS: The CHA2DS2-VASc score shows good performance in defining truly low-risk Asian patients with atrial fibrillation for stroke compared with CHADS2 and ATRIA scores.
© 2017 American Heart Association, Inc.

Entities:  

Keywords:  anticoagulants; atrial fibrillation; follow-up studies; risk; stroke

Mesh:

Substances:

Year:  2017        PMID: 28939672     DOI: 10.1161/STROKEAHA.117.018551

Source DB:  PubMed          Journal:  Stroke        ISSN: 0039-2499            Impact factor:   7.914


  23 in total

1.  Dynamic stroke risk scores of atrial fibrillation.

Authors:  Minjae Yoon; Boyoung Joung
Journal:  J Thorac Dis       Date:  2018-03       Impact factor: 2.895

2.  Prevalence and risk factors of left atrial thrombus in patients with atrial fibrillation and lower class (IIa) recommendation to anticoagulants.

Authors:  Beata Uziębło-Życzkowska; Paweł Krzesiński; Agnieszka Jurek; Monika Budnik; Iwona Gorczyca; Agnieszka Kapłon-Cieślicka; Marek Kiliszek; Agnieszka Wójcik; Monika Gawałko; Olga Jelonek; Anna Michalska; Katarzyna Starzyk; Piotr Scisło; Janusz Kochanowski; Krzysztof J Filipiak; Beata Wożakowska-Kapłon; Grzegorz Opolski; Grzegorz Gielerak
Journal:  Cardiovasc Diagn Ther       Date:  2020-08

3.  Application of the simple atrial fibrillation better care pathway for integrated care management in frail patients with atrial fibrillation: A nationwide cohort study.

Authors:  Pil-Sung Yang; Jung-Hoon Sung; Eunsun Jang; Hee Tae Yu; Tae-Hoon Kim; Gregory Y H Lip; Boyoung Joung
Journal:  J Arrhythm       Date:  2020-06-05

4.  Nation-Wide Use of Periprocedural Bridging Anticoagulation in Patients With Atrial Fibrillation.

Authors:  Geoffrey D Barnes; Kristian Seiler; Patrick Brady; Neil Kamdar
Journal:  Am J Cardiol       Date:  2019-08-23       Impact factor: 2.778

5.  A Simple Clinical Risk Score (C2HEST) for Predicting Incident Atrial Fibrillation in Asian Subjects: Derivation in 471,446 Chinese Subjects, With Internal Validation and External Application in 451,199 Korean Subjects.

Authors:  Yan-Guang Li; Daniele Pastori; Alessio Farcomeni; Pil-Sung Yang; Eunsun Jang; Boyoung Joung; Yu-Tang Wang; Yu-Tao Guo; Gregory Y H Lip
Journal:  Chest       Date:  2018-10-04       Impact factor: 9.410

6.  Integrated Care in Atrial Fibrillation: A Road Map to the Future.

Authors:  Aditya Bhat; Shaun Khanna; Henry H L Chen; Arnav Gupta; Gary C H Gan; A Robert Denniss; C Raina MacIntyre; Timothy C Tan
Journal:  Circ Cardiovasc Qual Outcomes       Date:  2021-03-05

7.  Increased Cardiac Arrhythmia After Pregnancy-Induced Hypertension: A South Korean Nationwide Database Study.

Authors:  Yoonjee Park; Geum Joon Cho; Seung-Young Roh; Jin Oh Na; Min-Jeong Oh
Journal:  J Am Heart Assoc       Date:  2022-01-11       Impact factor: 6.106

Review 8.  Cardiovascular Research Using the Korean National Health Information Database.

Authors:  Eue Keun Choi
Journal:  Korean Circ J       Date:  2020-05-20       Impact factor: 3.243

Review 9.  2018 Korean Guideline of Atrial Fibrillation Management.

Authors:  Boyoung Joung; Jung Myung Lee; Ki Hong Lee; Tae Hoon Kim; Eue Keun Choi; Woo Hyun Lim; Ki Woon Kang; Jaemin Shim; Hong Euy Lim; Junbeom Park; So Ryoung Lee; Young Soo Lee; Jin Bae Kim
Journal:  Korean Circ J       Date:  2018-12       Impact factor: 3.243

10.  Variations of Prevalence and Incidence of Atrial Fibrillation and Oral Anticoagulation Rate According to Different Analysis Approaches.

Authors:  Pil-Sung Yang; Soorack Ryu; Daehoon Kim; Eunsun Jang; Hee Tae Yu; Tae-Hoon Kim; Jinseub Hwang; Boyoung Joung; Gregory Y H Lip
Journal:  Sci Rep       Date:  2018-05-01       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.